Department of Obstetrics, Gynecology and Reproductive Health, D-Maternal Fetal Medicine, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.
Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, Newark, NJ, USA.
Stem Cell Rev Rep. 2022 Dec;18(8):3066-3082. doi: 10.1007/s12015-022-10419-8. Epub 2022 Jul 31.
Preeclampsia (PE) is a pregnancy-specific disease, occurring in ~ 2-10% of all pregnancies. PE is associated with increased maternal and perinatal morbidity and mortality, hypertension, proteinuria, disrupted artery remodeling, placental ischemia and reperfusion, and inflammation. The mechanism of PE pathogenesis remains unresolved explaining limited treatment. Aspirin is used to reduce the risk of developing PE. This study investigated aspirin's effect on PE-derived placenta mesenchymal stem cells (P-MSCs). P-MSCs from chorionic membrane (CM), chorionic villi, membranes from the maternal and amniotic regions, and umbilical cord were similar in morphology, phenotype and multipotency. Since CM-derived P-MSCs could undergo long-term passages, the experimental studies were conducted with this source of P-MSCs. Aspirin (1 mM) induced significant functional and transcriptomic changes in PE-derived P-MSCs, similar to healthy P-MSCs. These include cell cycle quiescence, improved angiogenic pathways, and immune suppressor potential. The latter indicated that aspirin could induce an indirect program to mitigate PE-associated inflammation. As a mediator of activating the DNA repair program, aspirin increased p53, and upregulated genes within the basic excision repair pathway. The robust ability for P-MSCs to maintain its function with high dose aspirin contrasted bone marrow (M) MSCs, which differentiated with eventual senescence/aging with 100 fold less aspirin. This difference cautions how data from other MSC sources are extrapolated to evaluate PE pathogenesis. Dysfunction among P-MSCs in PE involves a network of multiple pathways that can be restored to an almost healthy functional P-MSC. The findings could lead to targeted treatment for PE.
子痫前期(PE)是一种妊娠特有的疾病,发生在所有妊娠中的~2-10%。PE 与母体和围产期发病率和死亡率增加、高血压、蛋白尿、动脉重塑受损、胎盘缺血再灌注和炎症有关。PE 发病机制的机制仍未解决,解释了治疗方法有限。阿司匹林用于降低发生 PE 的风险。本研究调查了阿司匹林对 PE 衍生胎盘间充质干细胞(P-MSCs)的影响。来自绒毛膜(CM)、绒毛膜绒毛、母膜和羊膜区域以及脐带的 P-MSCs 在形态、表型和多能性方面相似。由于 CM 衍生的 P-MSCs 可以进行长期传代,因此使用这种来源的 P-MSCs 进行了实验研究。阿司匹林(1mM)在 PE 衍生的 P-MSCs 中诱导了显著的功能和转录组变化,与健康的 P-MSCs 相似。这些变化包括细胞周期静止、改善的血管生成途径和免疫抑制潜力。后者表明阿司匹林可以诱导一种间接程序来减轻与 PE 相关的炎症。作为激活 DNA 修复程序的介质,阿司匹林增加了 p53,并上调了碱基切除修复途径中的基因。P-MSCs 在高剂量阿司匹林作用下保持其功能的强大能力与骨髓(M)MSCs 形成对比,后者分化后用 100 倍少的阿司匹林最终出现衰老/老化。这种差异提醒人们如何从其他 MSC 来源推断数据来评估 PE 的发病机制。PE 中 P-MSCs 的功能障碍涉及多个途径的网络,可以恢复到几乎健康的功能性 P-MSC。这些发现可能为 PE 提供靶向治疗。